NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022

NuvOx Appoints Dr. Robert King to SAB

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022

NuvOx Technology Featured in Prominent Peer Review Journal

NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022

NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program

On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022

NuvOx to Participate in the BIO CEO Investor Conference

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022

NuvOx to Present at Various Bio Forums in JPM Week

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that... - October 12, 2021

NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer

NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke

NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021

NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM

NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021

NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors

NuvOx Pharma today announced that Jon S. Saxe has joined its Board of Directors. Saxe brings to NuvOx many years of experience from the biotechnology, pharmaceutical and venture capital industries. He has served as a director of more than 25 companies and currently is a director of several... - December 28, 2020

NuvOx Pharma US Patent Issuance - Radiotherapy and Chemotherapy with an Oxygen Therapeutic

NuvOx Pharma, Inc, a clinical stage biopharmaceutical company developing NanO2TM emulsion for oxygen delivery today announced the issuance of US Patent 10,456,468 – Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic. NanO2TM emulsion is designed to increase tumor oxygen... - November 03, 2019

NuvOx Pharma Receives $2M SBIR Grant for Pancreatic Cancer Diagnostic Development

Evan Unger, MD, President and CEO of NuvOx Pharma, announced that NuvOx has received a $2M Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute to fund the development of a new strategy to detect pancreatic cancer. The grant, 2R44CA203090-02, entitled... - July 14, 2018

NINDS Awards $150,000 Grant to NuvOx Pharma for Development of Field-Ready Syringe for Oxygen Delivery Drug

NuvOx Pharma, a clinical stage biotechnology company, has received a Phase I SBIR grant for $150,000 from the National Institutes of Health, specifically the National Institute of Neurological Diseases and Stroke (NINDS). This grant will fund development of a novel syringe sonication device that... - December 30, 2017

The NHLBI Grants NuvOx Pharma a 300K Grant to Study the Effects of Their Oxygen Therapeutic on Myocardial Infarction in a Pig Model

The National Heart, Lung, and Blood Institute (NHLBI) has awarded a grant for $317,743 for a study in pigs for NuvOx Pharma's drug, NVX-308, in heart attack. - April 14, 2017

NuvOx Pharma and Jiangsu Nhwa Pharmaceutical Co., Ltd. Sign Licensing Agreement for Hemorrhagic Shock and Perioperative Blood Loss

NuvOx Pharma LLC and Jiangsu Nhwa Pharmaceutical Co., Ltd. have signed a licensing agreement for the exclusive development and sales of NVX-408 for China for treating hemorrhagic shock and perioperative blood loss. NVX-408 is an oxygen therapeutic that is injected intravenously, flows through the... - January 26, 2017

NuvOx Pharma Awarded NIH Grant to Develop Technology to Increase Sensitivity and Specificity of Breast Cancer Diagnosis

NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the National Cancer Institute for $298,820.00 entitled, “B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the... - November 03, 2016

NuvOx Pharma Awarded NIH Grant to Develop Technology to Treat Endocarditis

NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for... - August 27, 2016

FDA Allows NuvOx Pharma’s IND to Initiate Phase Ib Clinical Trial in Stroke

Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients. The trial will be performed at the University of Arkansas Medical System in... - August 22, 2016

NuvOx Pharma Awarded STTR Grant from NCI for Ultrasound Contrast Agent to Diagnose Pancreatic Cancer

Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer... - May 28, 2016

NuvOx Pharma receives FDA Orphan Drug Designation for Oxygen Therapeutic for Vaso-occlusive Crisis and Acute Chest Syndrome in Sickle Cell Disease

Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of... - February 14, 2016

NuvOx Pharma Announces FDA Acceptance of IND to Initiate Clinical Trial for Vaso-Occlusive Crisis in Sickle Cell Disease

The FDA has notified NuvOx Pharma that it may proceed with a clinical trial for its Investigational New Drug (IND), NVX-508 for vaso-occlusive crisis (VOC) and acute chest syndrome (ACS) in sickle cell disease. VOC is one of the most severe complications of sickle cell disease and it typically... - February 13, 2016

NuvOx Pharma Receives FDA Orphan Drug Designation for Radiosensitizer for Glioblastoma

Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational drug NVX-108 for treatment of Glioblastoma. Orphan status provides NuvOx with development and commercial incentives such as tax credits for qualified clinical testing and market exclusivity for 7 years after the marketing approval is granted. - December 07, 2015

Press Releases 1 - 24 of 24